Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The chimeric anti-CEA antibody conjugated with DyLight 488 is a research-stage fluorescent imaging probe designed for the detection of tumors overexpressing carcinoembryonic antigen (CEA). It consists of a chimeric (mouse-human) monoclonal antibody covalently linked to DyLight 488, a green-fluorescent dye with excitation and emission peaks at approximately 493 nm and 518 nm, respectively. Developed for fluorescence-guided surgery and tumor imaging, the conjugate has been evaluated in preclinical orthotopic mouse models of pancreatic cancer. While it effectively labels CEA-positive neoplastic tissue, its utility in deep-tissue imaging is limited by the relatively poor tissue penetration of the 488 nm wavelength compared to longer-wavelength fluorophores, typically requiring superficial tumor locations for optimal detection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chimeric anti-CEA antibody conjugated with DyLight 488.